semaglutide in kidney disease FDA Approves to Reduce Disease, Cardiovascular Death Risk Adults With Type 2 Diabetes, Chronic Kidney Long-term kidney outcomes of semaglutide

Some patients may transition smoothly from compounded to branded GLP-1s

Popular GLP-1 Options for Weight Loss Over the past several years, GLP-1 receptor agonists have moved from being niche diabetes treatments to some of the most widely discussed weight-loss medications in the world

Gastroparesis can lead to dangerous dehydration and malnutrition that require emergency treatment

Women should track ovulatory markers, such as basal body temperature, luteinizing hormone surge kits, and mid-luteal progesterone, alongside serum hormone panels to judge response

Risk of Lipohypertrophy or Lipoatrophy: Repeated injections in the same spot can lead to fatty lumps under the skin

The consumer DTC model is limited to cash-paying patients outside the insurance system a real but niche population